APO Research
Talk to an analyst

APO RESEARCH · REPORT

γ-Aminobutyric Acid Receptor Agonists

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global γ-Aminobutyric Acid Receptor Agonists Market Outlook and Growth Opportunities 2026

20 December 2025219 pages

Choose your research edition.

Industry Researchγ-Aminobutyric Acid Receptor Agonists Industry Research Report 2026143 pages · $2,950 USDIndustry Growth & TrendsGlobal γ-Aminobutyric Acid Receptor Agonists Industry Growth and Trends Forecast to 2032128 pages · $3,450 USDMarket StructureGlobal γ-Aminobutyric Acid Receptor Agonists Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal γ-Aminobutyric Acid Receptor Agonists Market Outlook and Growth Opportunities 2026219 pages · $4,250 USDMarket Analysis & ForecastGlobal γ-Aminobutyric Acid Receptor Agonists Market Analysis and Forecast 2026-2032217 pages · $4,950 USD

Market perspective

The global γ-Aminobutyric Acid Receptor Agonists market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for γ-Aminobutyric Acid Receptor Agonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for γ-Aminobutyric Acid Receptor Agonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for γ-Aminobutyric Acid Receptor Agonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the γ-Aminobutyric Acid Receptor Agonists market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the γ-Aminobutyric Acid Receptor Agonists market include Akorn, Apotex, CHEPLAPHARM, Hikma, Jazz Pharmaceuicals, Neurelis, SAGE Therapeutics, Sandoz and Torrent Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global γ-Aminobutyric Acid Receptor Agonists market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of γ-Aminobutyric Acid Receptor Agonists and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents γ-Aminobutyric Acid Receptor Agonists sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the γ-Aminobutyric Acid Receptor Agonists market size, projected growth trends, production technologies, key applications, and end-use industries.

γ-Aminobutyric Acid Receptor Agonists Segment by Company

Akorn

Apotex

CHEPLAPHARM

Hikma

Jazz Pharmaceuicals

Neurelis

SAGE Therapeutics

Sandoz

Torrent Pharma

Viatris

WG Critical Care

AstraZeneca

Changzhou Siyao Pharmaceutical

Fresenius Kabi

GSK

Sichuan HaiscoPharmaceuical

Huazhong Pharmaceutical

Pfizer

Roche

Mylan

Novartis

Sanofi

Shanghai Pharmaceuticals Holding

Sun Pharma

Teva

Takeda

γ-Aminobutyric Acid Receptor Agonists Segment by Type

GABAA Receptors

GABAB Receptors

GABAC Receptors

γ-Aminobutyric Acid Receptor Agonists Segment by Application

Epilepsy

Anxiety

Neuropathic Pain

Insomnia

Other

γ-Aminobutyric Acid Receptor Agonists Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global γ-Aminobutyric Acid Receptor Agonists status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions γ-Aminobutyric Acid Receptor Agonists market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify γ-Aminobutyric Acid Receptor Agonists significant trends, drivers, influence factors in global and regions.

6. To analyze γ-Aminobutyric Acid Receptor Agonists competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global γ-Aminobutyric Acid Receptor Agonists market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of γ-Aminobutyric Acid Receptor Agonists and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of γ-Aminobutyric Acid Receptor Agonists.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the γ-Aminobutyric Acid Receptor Agonists market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global γ-Aminobutyric Acid Receptor Agonists industry.

Chapter 3: Detailed analysis of γ-Aminobutyric Acid Receptor Agonists manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of γ-Aminobutyric Acid Receptor Agonists in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of γ-Aminobutyric Acid Receptor Agonists in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. γ-Aminobutyric Acid Receptor Agonists Industry Trends Table 2. γ-Aminobutyric Acid Receptor Agonists Industry Drivers Table 3. γ-Aminobutyric Acid Receptor Agonists Industry Opportunities and Challenges Table 4. γ-Aminobutyric Acid Receptor Agonists Industry Restraints Table 5. Global γ-Aminobutyric Acid Receptor Agonists Revenue by Company (US$ Million) & (2021-2026) Table 6. Global γ-Aminobutyric Acid Receptor Agonists Revenue Share by Company (2021-2026) Table 7. Global γ-Aminobutyric Acid Receptor Agonists Sales Volume by Company (K Units) & (2021-2026) Table 8. Global γ-Aminobutyric Acid Receptor Agonists Sales Volume Share by Company (2021-2026) Table 9. Global γ-Aminobutyric Acid Receptor Agonists Average Price (US$/Unit) of Company (2021-2026) Table 10. Global γ-Aminobutyric Acid Receptor Agonists Company Ranking, (2024-2026) & (USD Million) Table 11. Global γ-Aminobutyric Acid Receptor Agonists Key Company Manufacturing Base & Headquarters Table 12. Global γ-Aminobutyric Acid Receptor Agonists Company, Product Type & Application Table 13. Global γ-Aminobutyric Acid Receptor Agonists Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global γ-Aminobutyric Acid Receptor Agonists by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of GABAA Receptors Table 18. Significant Companies of GABAB Receptors Table 19. Significant Companies of GABAC Receptors Table 20. Global γ-Aminobutyric Acid Receptor Agonists Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global γ-Aminobutyric Acid Receptor Agonists Sales Volume by Type (2021-2026) & (K Units) Table 22. Global γ-Aminobutyric Acid Receptor Agonists Sales Volume by Type (2027-2032) & (K Units) Table 23. Global γ-Aminobutyric Acid Receptor Agonists Sales Volume Share by Type (2021-2026) Table 24. Global γ-Aminobutyric Acid Receptor Agonists Sales Volume Share by Type (2027-2032) Table 25. Global γ-Aminobutyric Acid Receptor Agonists Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global γ-Aminobutyric Acid Receptor Agonists Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global γ-Aminobutyric Acid Receptor Agonists Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Type (2021-2026) Table 29. Global γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Epilepsy Table 31. Significant Companies of Anxiety Table 32. Significant Companies of Neuropathic Pain Table 33. Significant Companies of Insomnia Table 34. Significant Companies of Other Table 35. Global γ-Aminobutyric Acid Receptor Agonists Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global γ-Aminobutyric Acid Receptor Agonists Sales Volume by Application (2021-2026) & (K Units) Table 37. Global γ-Aminobutyric Acid Receptor Agonists Sales Volume by Application (2027-2032) & (K Units) Table 38. Global γ-Aminobutyric Acid Receptor Agonists Sales Volume Share by Application (2021-2026) Table 39. Global γ-Aminobutyric Acid Receptor Agonists Sales Volume Share by Application (2027-2032) Table 40. Global γ-Aminobutyric Acid Receptor Agonists Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global γ-Aminobutyric Acid Receptor Agonists Sales Value by Application (2021-2026) & (US$ Million) Table 42. Global γ-Aminobutyric Acid Receptor Agonists Sales Value by Application (2027-2032) & (US$ Million) Table 43. Global γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Application (2021-2026) Table 44. Global γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Application (2027-2032) Table 45. Global γ-Aminobutyric Acid Receptor Agonists Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 46. Global γ-Aminobutyric Acid Receptor Agonists Sales by Region (2021-2026) & (K Units) Table 47. Global γ-Aminobutyric Acid Receptor Agonists Sales Market Share by Region (2021-2026) Table 48. Global γ-Aminobutyric Acid Receptor Agonists Sales by Region (2027-2032) & (K Units) Table 49. Global γ-Aminobutyric Acid Receptor Agonists Sales Market Share by Region (2027-2032) Table 50. Global γ-Aminobutyric Acid Receptor Agonists Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global γ-Aminobutyric Acid Receptor Agonists Sales Value by Region (2021-2026) & (US$ Million) Table 52. Global γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Region (2021-2026) Table 53. Global γ-Aminobutyric Acid Receptor Agonists Sales Value by Region (2027-2032) & (US$ Million) Table 54. Global γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Region (2027-2032) Table 55. Global γ-Aminobutyric Acid Receptor Agonists Market Average Price (US$/Unit) by Region (2021-2026) Table 56. Global γ-Aminobutyric Acid Receptor Agonists Market Average Price (US$/Unit) by Region (2027-2032) Table 57. Global γ-Aminobutyric Acid Receptor Agonists Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. Global γ-Aminobutyric Acid Receptor Agonists Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global γ-Aminobutyric Acid Receptor Agonists Sales by Country (2021-2026) & (K Units) Table 60. Global γ-Aminobutyric Acid Receptor Agonists Sales Market Share by Country (2021-2026) Table 61. Global γ-Aminobutyric Acid Receptor Agonists Sales by Country (2027-2032) & (K Units) Table 62. Global γ-Aminobutyric Acid Receptor Agonists Sales Market Share by Country (2027-2032) Table 63. Global γ-Aminobutyric Acid Receptor Agonists Sales Value by Country (2021-2026) & (US$ Million) Table 64. Global γ-Aminobutyric Acid Receptor Agonists Sales Value Market Share by Country (2021-2026) Table 65. Global γ-Aminobutyric Acid Receptor Agonists Sales Value by Country (2027-2032) & (US$ Million) Table 66. Global γ-Aminobutyric Acid Receptor Agonists Sales Value Market Share by Country (2027-2032) Table 67. Akorn Company Information Table 68. Akorn Business Overview Table 69. Akorn γ-Aminobutyric Acid Receptor Agonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 70. Akorn γ-Aminobutyric Acid Receptor Agonists Product Portfolio Table 71. Akorn Recent Development Table 72. Apotex Company Information Table 73. Apotex Business Overview Table 74. Apotex γ-Aminobutyric Acid Receptor Agonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Apotex γ-Aminobutyric Acid Receptor Agonists Product Portfolio Table 76. Apotex Recent Development Table 77. CHEPLAPHARM Company Information Table 78. CHEPLAPHARM Business Overview Table 79. CHEPLAPHARM γ-Aminobutyric Acid Receptor Agonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. CHEPLAPHARM γ-Aminobutyric Acid Receptor Agonists Product Portfolio Table 81. CHEPLAPHARM Recent Development Table 82. Hikma Company Information Table 83. Hikma Business Overview Table 84. Hikma γ-Aminobutyric Acid Receptor Agonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Hikma γ-Aminobutyric Acid Receptor Agonists Product Portfolio Table 86. Hikma Recent Development Table 87. Jazz Pharmaceuicals Company Information Table 88. Jazz Pharmaceuicals Business Overview Table 89. Jazz Pharmaceuicals γ-Aminobutyric Acid Receptor Agonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Jazz Pharmaceuicals γ-Aminobutyric Acid Receptor Agonists Product Portfolio Table 91. Jazz Pharmaceuicals Recent Development Table 92. Neurelis Company Information Table 93. Neurelis Business Overview Table 94. Neurelis γ-Aminobutyric Acid Receptor Agonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Neurelis γ-Aminobutyric Acid Receptor Agonists Product Portfolio Table 96. Neurelis Recent Development Table 97. SAGE Therapeutics Company Information Table 98. SAGE Therapeutics Business Overview Table 99. SAGE Therapeutics γ-Aminobutyric Acid Receptor Agonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. SAGE Therapeutics γ-Aminobutyric Acid Receptor Agonists Product Portfolio Table 101. SAGE Therapeutics Recent Development Table 102. Sandoz Company Information Table 103. Sandoz Business Overview Table 104. Sandoz γ-Aminobutyric Acid Receptor Agonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Sandoz γ-Aminobutyric Acid Receptor Agonists Product Portfolio Table 106. Sandoz Recent Development Table 107. Torrent Pharma Company Information Table 108. Torrent Pharma Business Overview Table 109. Torrent Pharma γ-Aminobutyric Acid Receptor Agonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Torrent Pharma γ-Aminobutyric Acid Receptor Agonists Product Portfolio Table 111. Torrent Pharma Recent Development Table 112. Viatris Company Information Table 113. Viatris Business Overview Table 114. Viatris γ-Aminobutyric Acid Receptor Agonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. Viatris γ-Aminobutyric Acid Receptor Agonists Product Portfolio Table 116. Viatris Recent Development Table 117. WG Critical Care Company Information Table 118. WG Critical Care Business Overview Table 119. WG Critical Care γ-Aminobutyric Acid Receptor Agonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. WG Critical Care γ-Aminobutyric Acid Receptor Agonists Product Portfolio Table 121. WG Critical Care Recent Development Table 122. AstraZeneca Company Information Table 123. AstraZeneca Business Overview Table 124. AstraZeneca γ-Aminobutyric Acid Receptor Agonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 125. AstraZeneca γ-Aminobutyric Acid Receptor Agonists Product Portfolio Table 126. AstraZeneca Recent Development Table 127. Changzhou Siyao Pharmaceutical Company Information Table 128. Changzhou Siyao Pharmaceutical Business Overview Table 129. Changzhou Siyao Pharmaceutical γ-Aminobutyric Acid Receptor Agonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 130. Changzhou Siyao Pharmaceutical γ-Aminobutyric Acid Receptor Agonists Product Portfolio Table 131. Changzhou Siyao Pharmaceutical Recent Development Table 132. Fresenius Kabi Company Information Table 133. Fresenius Kabi Business Overview Table 134. Fresenius Kabi γ-Aminobutyric Acid Receptor Agonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 135. Fresenius Kabi γ-Aminobutyric Acid Receptor Agonists Product Portfolio Table 136. Fresenius Kabi Recent Development Table 137. GSK Company Information Table 138. GSK Business Overview Table 139. GSK γ-Aminobutyric Acid Receptor Agonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 140. GSK γ-Aminobutyric Acid Receptor Agonists Product Portfolio Table 141. GSK Recent Development Table 142. Sichuan HaiscoPharmaceuical Company Information Table 143. Sichuan HaiscoPharmaceuical Business Overview Table 144. Sichuan HaiscoPharmaceuical γ-Aminobutyric Acid Receptor Agonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 145. Sichuan HaiscoPharmaceuical γ-Aminobutyric Acid Receptor Agonists Product Portfolio Table 146. Sichuan HaiscoPharmaceuical Recent Development Table 147. Huazhong Pharmaceutical Company Information Table 148. Huazhong Pharmaceutical Business Overview Table 149. Huazhong Pharmaceutical γ-Aminobutyric Acid Receptor Agonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 150. Huazhong Pharmaceutical γ-Aminobutyric Acid Receptor Agonists Product Portfolio Table 151. Huazhong Pharmaceutical Recent Development Table 152. Pfizer Company Information Table 153. Pfizer Business Overview Table 154. Pfizer γ-Aminobutyric Acid Receptor Agonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 155. Pfizer γ-Aminobutyric Acid Receptor Agonists Product Portfolio Table 156. Pfizer Recent Development Table 157. Roche Company Information Table 158. Roche Business Overview Table 159. Roche γ-Aminobutyric Acid Receptor Agonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 160. Roche γ-Aminobutyric Acid Receptor Agonists Product Portfolio Table 161. Roche Recent Development Table 162. Mylan Company Information Table 163. Mylan Business Overview Table 164. Mylan γ-Aminobutyric Acid Receptor Agonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 165. Mylan γ-Aminobutyric Acid Receptor Agonists Product Portfolio Table 166. Mylan Recent Development Table 167. Novartis Company Information Table 168. Novartis Business Overview Table 169. Novartis γ-Aminobutyric Acid Receptor Agonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 170. Novartis γ-Aminobutyric Acid Receptor Agonists Product Portfolio Table 171. Novartis Recent Development Table 172. Sanofi Company Information Table 173. Sanofi Business Overview Table 174. Sanofi γ-Aminobutyric Acid Receptor Agonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 175. Sanofi γ-Aminobutyric Acid Receptor Agonists Product Portfolio Table 176. Sanofi Recent Development Table 177. Shanghai Pharmaceuticals Holding Company Information Table 178. Shanghai Pharmaceuticals Holding Business Overview Table 179. Shanghai Pharmaceuticals Holding γ-Aminobutyric Acid Receptor Agonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 180. Shanghai Pharmaceuticals Holding γ-Aminobutyric Acid Receptor Agonists Product Portfolio Table 181. Shanghai Pharmaceuticals Holding Recent Development Table 182. Sun Pharma Company Information Table 183. Sun Pharma Business Overview Table 184. Sun Pharma γ-Aminobutyric Acid Receptor Agonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 185. Sun Pharma γ-Aminobutyric Acid Receptor Agonists Product Portfolio Table 186. Sun Pharma Recent Development Table 187. Teva Company Information Table 188. Teva Business Overview Table 189. Teva γ-Aminobutyric Acid Receptor Agonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 190. Teva γ-Aminobutyric Acid Receptor Agonists Product Portfolio Table 191. Teva Recent Development Table 192. Takeda Company Information Table 193. Takeda Business Overview Table 194. Takeda γ-Aminobutyric Acid Receptor Agonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 195. Takeda γ-Aminobutyric Acid Receptor Agonists Product Portfolio Table 196. Takeda Recent Development Table 197. Key Raw Materials Table 198. Raw Materials Key Suppliers Table 199. γ-Aminobutyric Acid Receptor Agonists Distributors List Table 200. γ-Aminobutyric Acid Receptor Agonists Customers List Table 201. Research Programs/Design for This Report Table 202. Authors List of This Report Table 203. Secondary Sources Table 204. Primary Sources List of Figures Figure 1. γ-Aminobutyric Acid Receptor Agonists Product Image Figure 2. Global γ-Aminobutyric Acid Receptor Agonists Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global γ-Aminobutyric Acid Receptor Agonists Sales Value (2021-2032) & (US$ Million) Figure 4. Global γ-Aminobutyric Acid Receptor Agonists Sales (2021-2032) & (K Units) Figure 5. Global γ-Aminobutyric Acid Receptor Agonists Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global γ-Aminobutyric Acid Receptor Agonists Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. GABAA Receptors Image Figure 10. GABAB Receptors Image Figure 11. GABAC Receptors Image Figure 12. Global γ-Aminobutyric Acid Receptor Agonists Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global γ-Aminobutyric Acid Receptor Agonists Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global γ-Aminobutyric Acid Receptor Agonists Sales Volume Share by Type (2021-2032) Figure 15. Global γ-Aminobutyric Acid Receptor Agonists Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global γ-Aminobutyric Acid Receptor Agonists Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Type (2021-2032) Figure 18. Epilepsy Image Figure 19. Anxiety Image Figure 20. Neuropathic Pain Image Figure 21. Insomnia Image Figure 22. Other Image Figure 23. Global γ-Aminobutyric Acid Receptor Agonists Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global γ-Aminobutyric Acid Receptor Agonists Sales Volume Share 2021 VS 2025 VS 2032 Figure 25. Global γ-Aminobutyric Acid Receptor Agonists Sales Volume Share by Application (2021-2032) Figure 26. Global γ-Aminobutyric Acid Receptor Agonists Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global γ-Aminobutyric Acid Receptor Agonists Sales Value Share 2021 VS 2025 VS 2032 Figure 28. Global γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Application (2021-2032) Figure 29. Global γ-Aminobutyric Acid Receptor Agonists Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 30. Global γ-Aminobutyric Acid Receptor Agonists Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 31. Global γ-Aminobutyric Acid Receptor Agonists Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 32. Global γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 33. North America γ-Aminobutyric Acid Receptor Agonists Sales Value (2021-2032) & (US$ Million) Figure 34. North America γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Europe γ-Aminobutyric Acid Receptor Agonists Sales Value (2021-2032) & (US$ Million) Figure 36. Europe γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Asia-Pacific γ-Aminobutyric Acid Receptor Agonists Sales Value (2021-2032) & (US$ Million) Figure 38. Asia-Pacific γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Country (%), 2025 VS 2032 Figure 39. South America γ-Aminobutyric Acid Receptor Agonists Sales Value (2021-2032) & (US$ Million) Figure 40. South America γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Middle East & Africa γ-Aminobutyric Acid Receptor Agonists Sales Value (2021-2032) & (US$ Million) Figure 42. Middle East & Africa γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Country (%), 2025 VS 2032 Figure 43. USA γ-Aminobutyric Acid Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. USA γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. USA γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Canada γ-Aminobutyric Acid Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Canada γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Canada γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Mexico γ-Aminobutyric Acid Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Mexico γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Mexico γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Germany γ-Aminobutyric Acid Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Germany γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Germany γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. France γ-Aminobutyric Acid Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. France γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. France γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. U.K. γ-Aminobutyric Acid Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. U.K. γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. U.K. γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Italy γ-Aminobutyric Acid Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Italy γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Italy γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Spain γ-Aminobutyric Acid Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Spain γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Spain γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Russia γ-Aminobutyric Acid Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Russia γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Russia γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Netherlands γ-Aminobutyric Acid Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Netherlands γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Netherlands γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Nordic Countries γ-Aminobutyric Acid Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Nordic Countries γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Nordic Countries γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. China γ-Aminobutyric Acid Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. China γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. China γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Japan γ-Aminobutyric Acid Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Japan γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Japan γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. South Korea γ-Aminobutyric Acid Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. South Korea γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. South Korea γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. India γ-Aminobutyric Acid Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. India γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. India γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Australia γ-Aminobutyric Acid Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Australia γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Australia γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Southeast Asia γ-Aminobutyric Acid Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Southeast Asia γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Southeast Asia γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Brazil γ-Aminobutyric Acid Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Brazil γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Brazil γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Argentina γ-Aminobutyric Acid Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Argentina γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Argentina γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Chile γ-Aminobutyric Acid Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Chile γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Chile γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Colombia γ-Aminobutyric Acid Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Colombia γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Colombia γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Peru γ-Aminobutyric Acid Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Peru γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Peru γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Saudi Arabia γ-Aminobutyric Acid Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Saudi Arabia γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Saudi Arabia γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Israel γ-Aminobutyric Acid Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Israel Arabia γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Israel Arabia γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. UAE γ-Aminobutyric Acid Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. UAE γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. UAE γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Turkey γ-Aminobutyric Acid Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Turkey γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Turkey γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Iran γ-Aminobutyric Acid Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Iran γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Iran γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Egypt γ-Aminobutyric Acid Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Egypt γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Egypt γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. γ-Aminobutyric Acid Receptor Agonists Value Chain Figure 128. Manufacturing Cost Structure Figure 129. γ-Aminobutyric Acid Receptor Agonists Sales Mode & Process Figure 130. Direct Comparison with Distribution Share Figure 131. Distributors Profiles Figure 132. Years Considered Figure 133. Research Process Figure 134. Key Executives Interviewed

Scope & coverage.

Types
  • GABAA Receptors
  • GABAB Receptors
  • GABAC Receptors
Applications
  • Epilepsy
  • Anxiety
  • Neuropathic Pain
  • Insomnia
  • Other
Companies covered
  • Akorn
  • Apotex
  • CHEPLAPHARM
  • Hikma
  • Jazz Pharmaceuicals
  • Neurelis
  • SAGE Therapeutics
  • Sandoz
  • Torrent Pharma
  • Viatris
  • WG Critical Care
  • AstraZeneca
  • Changzhou Siyao Pharmaceutical
  • Fresenius Kabi
  • GSK
  • Sichuan HaiscoPharmaceuical
  • Huazhong Pharmaceutical
  • Pfizer
  • Roche
  • Mylan
  • Novartis
  • Sanofi
  • Shanghai Pharmaceuticals Holding
  • Sun Pharma
  • Teva
  • Takeda

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global γ-Aminobutyric Acid Receptor Agonists Sales Value (2021-2032)
  4. 1.2.2 Global γ-Aminobutyric Acid Receptor Agonists Sales Volume (2021-2032)
  5. 1.2.3 Global γ-Aminobutyric Acid Receptor Agonists Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 γ-Aminobutyric Acid Receptor Agonists Market Dynamics
  1. 2.1 γ-Aminobutyric Acid Receptor Agonists Industry Trends
  2. 2.2 γ-Aminobutyric Acid Receptor Agonists Industry Drivers
  3. 2.3 γ-Aminobutyric Acid Receptor Agonists Industry Opportunities and Challenges
  4. 2.4 γ-Aminobutyric Acid Receptor Agonists Industry Restraints
3 γ-Aminobutyric Acid Receptor Agonists Market by Company
  1. 3.1 Global γ-Aminobutyric Acid Receptor Agonists Company Revenue Ranking in 2025
  2. 3.2 Global γ-Aminobutyric Acid Receptor Agonists Revenue by Company (2021-2026)
  3. 3.3 Global γ-Aminobutyric Acid Receptor Agonists Sales Volume by Company (2021-2026)
  4. 3.4 Global γ-Aminobutyric Acid Receptor Agonists Average Price by Company (2021-2026)
  5. 3.5 Global γ-Aminobutyric Acid Receptor Agonists Company Ranking (2024-2026)
  6. 3.6 Global γ-Aminobutyric Acid Receptor Agonists Company Manufacturing Base and Headquarters
  7. 3.7 Global γ-Aminobutyric Acid Receptor Agonists Company Product Type and Application
  8. 3.8 Global γ-Aminobutyric Acid Receptor Agonists Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global γ-Aminobutyric Acid Receptor Agonists Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 γ-Aminobutyric Acid Receptor Agonists Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 γ-Aminobutyric Acid Receptor Agonists Market by Type
  1. 4.1 γ-Aminobutyric Acid Receptor Agonists Type Introduction
  2. 4.1.1 GABAA Receptors
  3. 4.1.2 GABAB Receptors
  4. 4.1.3 GABAC Receptors
  5. 4.2 Global γ-Aminobutyric Acid Receptor Agonists Sales Volume by Type
  6. 4.2.1 Global γ-Aminobutyric Acid Receptor Agonists Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global γ-Aminobutyric Acid Receptor Agonists Sales Volume by Type (2021-2032)
  8. 4.2.3 Global γ-Aminobutyric Acid Receptor Agonists Sales Volume Share by Type (2021-2032)
  9. 4.3 Global γ-Aminobutyric Acid Receptor Agonists Sales Value by Type
  10. 4.3.1 Global γ-Aminobutyric Acid Receptor Agonists Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global γ-Aminobutyric Acid Receptor Agonists Sales Value by Type (2021-2032)
  12. 4.3.3 Global γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Type (2021-2032)
5 γ-Aminobutyric Acid Receptor Agonists Market by Application
  1. 5.1 γ-Aminobutyric Acid Receptor Agonists Application Introduction
  2. 5.1.1 Epilepsy
  3. 5.1.2 Anxiety
  4. 5.1.3 Neuropathic Pain
  5. 5.1.4 Insomnia
  6. 5.1.5 Other
  7. 5.2 Global γ-Aminobutyric Acid Receptor Agonists Sales Volume by Application
  8. 5.2.1 Global γ-Aminobutyric Acid Receptor Agonists Sales Volume by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global γ-Aminobutyric Acid Receptor Agonists Sales Volume by Application (2021-2032)
  10. 5.2.3 Global γ-Aminobutyric Acid Receptor Agonists Sales Volume Share by Application (2021-2032)
  11. 5.3 Global γ-Aminobutyric Acid Receptor Agonists Sales Value by Application
  12. 5.3.1 Global γ-Aminobutyric Acid Receptor Agonists Sales Value by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global γ-Aminobutyric Acid Receptor Agonists Sales Value by Application (2021-2032)
  14. 5.3.3 Global γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Application (2021-2032)
6 γ-Aminobutyric Acid Receptor Agonists Regional Sales and Value Analysis
  1. 6.1 Global γ-Aminobutyric Acid Receptor Agonists Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global γ-Aminobutyric Acid Receptor Agonists Sales by Region (2021-2032)
  3. 6.2.1 Global γ-Aminobutyric Acid Receptor Agonists Sales by Region: 2021-2026
  4. 6.2.2 Global γ-Aminobutyric Acid Receptor Agonists Sales by Region (2027-2032)
  5. 6.3 Global γ-Aminobutyric Acid Receptor Agonists Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global γ-Aminobutyric Acid Receptor Agonists Sales Value by Region (2021-2032)
  7. 6.4.1 Global γ-Aminobutyric Acid Receptor Agonists Sales Value by Region: 2021-2026
  8. 6.4.2 Global γ-Aminobutyric Acid Receptor Agonists Sales Value by Region (2027-2032)
  9. 6.5 Global γ-Aminobutyric Acid Receptor Agonists Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America γ-Aminobutyric Acid Receptor Agonists Sales Value (2021-2032)
  12. 6.6.2 North America γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe γ-Aminobutyric Acid Receptor Agonists Sales Value (2021-2032)
  15. 6.7.2 Europe γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific γ-Aminobutyric Acid Receptor Agonists Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America γ-Aminobutyric Acid Receptor Agonists Sales Value (2021-2032)
  21. 6.9.2 South America γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa γ-Aminobutyric Acid Receptor Agonists Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Country, 2025 VS 2032
7 γ-Aminobutyric Acid Receptor Agonists Country-level Sales and Value Analysis
  1. 7.1 Global γ-Aminobutyric Acid Receptor Agonists Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global γ-Aminobutyric Acid Receptor Agonists Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global γ-Aminobutyric Acid Receptor Agonists Sales by Country (2021-2032)
  4. 7.3.1 Global γ-Aminobutyric Acid Receptor Agonists Sales by Country (2021-2026)
  5. 7.3.2 Global γ-Aminobutyric Acid Receptor Agonists Sales by Country (2027-2032)
  6. 7.4 Global γ-Aminobutyric Acid Receptor Agonists Sales Value by Country (2021-2032)
  7. 7.4.1 Global γ-Aminobutyric Acid Receptor Agonists Sales Value by Country (2021-2026)
  8. 7.4.2 Global γ-Aminobutyric Acid Receptor Agonists Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA γ-Aminobutyric Acid Receptor Agonists Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada γ-Aminobutyric Acid Receptor Agonists Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico γ-Aminobutyric Acid Receptor Agonists Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany γ-Aminobutyric Acid Receptor Agonists Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France γ-Aminobutyric Acid Receptor Agonists Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. γ-Aminobutyric Acid Receptor Agonists Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy γ-Aminobutyric Acid Receptor Agonists Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain γ-Aminobutyric Acid Receptor Agonists Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia γ-Aminobutyric Acid Receptor Agonists Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands γ-Aminobutyric Acid Receptor Agonists Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries γ-Aminobutyric Acid Receptor Agonists Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China γ-Aminobutyric Acid Receptor Agonists Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan γ-Aminobutyric Acid Receptor Agonists Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea γ-Aminobutyric Acid Receptor Agonists Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India γ-Aminobutyric Acid Receptor Agonists Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia γ-Aminobutyric Acid Receptor Agonists Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia γ-Aminobutyric Acid Receptor Agonists Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil γ-Aminobutyric Acid Receptor Agonists Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina γ-Aminobutyric Acid Receptor Agonists Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile γ-Aminobutyric Acid Receptor Agonists Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia γ-Aminobutyric Acid Receptor Agonists Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru γ-Aminobutyric Acid Receptor Agonists Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia γ-Aminobutyric Acid Receptor Agonists Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel γ-Aminobutyric Acid Receptor Agonists Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE γ-Aminobutyric Acid Receptor Agonists Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey γ-Aminobutyric Acid Receptor Agonists Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran γ-Aminobutyric Acid Receptor Agonists Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt γ-Aminobutyric Acid Receptor Agonists Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt γ-Aminobutyric Acid Receptor Agonists Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Akorn
  2. 8.1.1 Akorn Company Information
  3. 8.1.2 Akorn Business Overview
  4. 8.1.3 Akorn γ-Aminobutyric Acid Receptor Agonists Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Akorn γ-Aminobutyric Acid Receptor Agonists Product Portfolio
  6. 8.1.5 Akorn Recent Developments
  7. 8.2 Apotex
  8. 8.2.1 Apotex Company Information
  9. 8.2.2 Apotex Business Overview
  10. 8.2.3 Apotex γ-Aminobutyric Acid Receptor Agonists Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Apotex γ-Aminobutyric Acid Receptor Agonists Product Portfolio
  12. 8.2.5 Apotex Recent Developments
  13. 8.3 CHEPLAPHARM
  14. 8.3.1 CHEPLAPHARM Company Information
  15. 8.3.2 CHEPLAPHARM Business Overview
  16. 8.3.3 CHEPLAPHARM γ-Aminobutyric Acid Receptor Agonists Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 CHEPLAPHARM γ-Aminobutyric Acid Receptor Agonists Product Portfolio
  18. 8.3.5 CHEPLAPHARM Recent Developments
  19. 8.4 Hikma
  20. 8.4.1 Hikma Company Information
  21. 8.4.2 Hikma Business Overview
  22. 8.4.3 Hikma γ-Aminobutyric Acid Receptor Agonists Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Hikma γ-Aminobutyric Acid Receptor Agonists Product Portfolio
  24. 8.4.5 Hikma Recent Developments
  25. 8.5 Jazz Pharmaceuicals
  26. 8.5.1 Jazz Pharmaceuicals Company Information
  27. 8.5.2 Jazz Pharmaceuicals Business Overview
  28. 8.5.3 Jazz Pharmaceuicals γ-Aminobutyric Acid Receptor Agonists Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Jazz Pharmaceuicals γ-Aminobutyric Acid Receptor Agonists Product Portfolio
  30. 8.5.5 Jazz Pharmaceuicals Recent Developments
  31. 8.6 Neurelis
  32. 8.6.1 Neurelis Company Information
  33. 8.6.2 Neurelis Business Overview
  34. 8.6.3 Neurelis γ-Aminobutyric Acid Receptor Agonists Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Neurelis γ-Aminobutyric Acid Receptor Agonists Product Portfolio
  36. 8.6.5 Neurelis Recent Developments
  37. 8.7 SAGE Therapeutics
  38. 8.7.1 SAGE Therapeutics Company Information
  39. 8.7.2 SAGE Therapeutics Business Overview
  40. 8.7.3 SAGE Therapeutics γ-Aminobutyric Acid Receptor Agonists Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 SAGE Therapeutics γ-Aminobutyric Acid Receptor Agonists Product Portfolio
  42. 8.7.5 SAGE Therapeutics Recent Developments
  43. 8.8 Sandoz
  44. 8.8.1 Sandoz Company Information
  45. 8.8.2 Sandoz Business Overview
  46. 8.8.3 Sandoz γ-Aminobutyric Acid Receptor Agonists Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Sandoz γ-Aminobutyric Acid Receptor Agonists Product Portfolio
  48. 8.8.5 Sandoz Recent Developments
  49. 8.9 Torrent Pharma
  50. 8.9.1 Torrent Pharma Company Information
  51. 8.9.2 Torrent Pharma Business Overview
  52. 8.9.3 Torrent Pharma γ-Aminobutyric Acid Receptor Agonists Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Torrent Pharma γ-Aminobutyric Acid Receptor Agonists Product Portfolio
  54. 8.9.5 Torrent Pharma Recent Developments
  55. 8.10 Viatris
  56. 8.10.1 Viatris Company Information
  57. 8.10.2 Viatris Business Overview
  58. 8.10.3 Viatris γ-Aminobutyric Acid Receptor Agonists Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Viatris γ-Aminobutyric Acid Receptor Agonists Product Portfolio
  60. 8.10.5 Viatris Recent Developments
  61. 8.11 WG Critical Care
  62. 8.11.1 WG Critical Care Company Information
  63. 8.11.2 WG Critical Care Business Overview
  64. 8.11.3 WG Critical Care γ-Aminobutyric Acid Receptor Agonists Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 WG Critical Care γ-Aminobutyric Acid Receptor Agonists Product Portfolio
  66. 8.11.5 WG Critical Care Recent Developments
  67. 8.12 AstraZeneca
  68. 8.12.1 AstraZeneca Company Information
  69. 8.12.2 AstraZeneca Business Overview
  70. 8.12.3 AstraZeneca γ-Aminobutyric Acid Receptor Agonists Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 AstraZeneca γ-Aminobutyric Acid Receptor Agonists Product Portfolio
  72. 8.12.5 AstraZeneca Recent Developments
  73. 8.13 Changzhou Siyao Pharmaceutical
  74. 8.13.1 Changzhou Siyao Pharmaceutical Company Information
  75. 8.13.2 Changzhou Siyao Pharmaceutical Business Overview
  76. 8.13.3 Changzhou Siyao Pharmaceutical γ-Aminobutyric Acid Receptor Agonists Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Changzhou Siyao Pharmaceutical γ-Aminobutyric Acid Receptor Agonists Product Portfolio
  78. 8.13.5 Changzhou Siyao Pharmaceutical Recent Developments
  79. 8.14 Fresenius Kabi
  80. 8.14.1 Fresenius Kabi Company Information
  81. 8.14.2 Fresenius Kabi Business Overview
  82. 8.14.3 Fresenius Kabi γ-Aminobutyric Acid Receptor Agonists Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Fresenius Kabi γ-Aminobutyric Acid Receptor Agonists Product Portfolio
  84. 8.14.5 Fresenius Kabi Recent Developments
  85. 8.15 GSK
  86. 8.15.1 GSK Company Information
  87. 8.15.2 GSK Business Overview
  88. 8.15.3 GSK γ-Aminobutyric Acid Receptor Agonists Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 GSK γ-Aminobutyric Acid Receptor Agonists Product Portfolio
  90. 8.15.5 GSK Recent Developments
  91. 8.16 Sichuan HaiscoPharmaceuical
  92. 8.16.1 Sichuan HaiscoPharmaceuical Company Information
  93. 8.16.2 Sichuan HaiscoPharmaceuical Business Overview
  94. 8.16.3 Sichuan HaiscoPharmaceuical γ-Aminobutyric Acid Receptor Agonists Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Sichuan HaiscoPharmaceuical γ-Aminobutyric Acid Receptor Agonists Product Portfolio
  96. 8.16.5 Sichuan HaiscoPharmaceuical Recent Developments
  97. 8.17 Huazhong Pharmaceutical
  98. 8.17.1 Huazhong Pharmaceutical Company Information
  99. 8.17.2 Huazhong Pharmaceutical Business Overview
  100. 8.17.3 Huazhong Pharmaceutical γ-Aminobutyric Acid Receptor Agonists Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Huazhong Pharmaceutical γ-Aminobutyric Acid Receptor Agonists Product Portfolio
  102. 8.17.5 Huazhong Pharmaceutical Recent Developments
  103. 8.18 Pfizer
  104. 8.18.1 Pfizer Company Information
  105. 8.18.2 Pfizer Business Overview
  106. 8.18.3 Pfizer γ-Aminobutyric Acid Receptor Agonists Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Pfizer γ-Aminobutyric Acid Receptor Agonists Product Portfolio
  108. 8.18.5 Pfizer Recent Developments
  109. 8.19 Roche
  110. 8.19.1 Roche Company Information
  111. 8.19.2 Roche Business Overview
  112. 8.19.3 Roche γ-Aminobutyric Acid Receptor Agonists Sales, Value and Gross Margin (2021-2026)
  113. 8.19.4 Roche γ-Aminobutyric Acid Receptor Agonists Product Portfolio
  114. 8.19.5 Roche Recent Developments
  115. 8.20 Mylan
  116. 8.20.1 Mylan Company Information
  117. 8.20.2 Mylan Business Overview
  118. 8.20.3 Mylan γ-Aminobutyric Acid Receptor Agonists Sales, Value and Gross Margin (2021-2026)
  119. 8.20.4 Mylan γ-Aminobutyric Acid Receptor Agonists Product Portfolio
  120. 8.20.5 Mylan Recent Developments
  121. 8.21 Novartis
  122. 8.21.1 Novartis Company Information
  123. 8.21.2 Novartis Business Overview
  124. 8.21.3 Novartis γ-Aminobutyric Acid Receptor Agonists Sales, Value and Gross Margin (2021-2026)
  125. 8.21.4 Novartis γ-Aminobutyric Acid Receptor Agonists Product Portfolio
  126. 8.21.5 Novartis Recent Developments
  127. 8.22 Sanofi
  128. 8.22.1 Sanofi Company Information
  129. 8.22.2 Sanofi Business Overview
  130. 8.22.3 Sanofi γ-Aminobutyric Acid Receptor Agonists Sales, Value and Gross Margin (2021-2026)
  131. 8.22.4 Sanofi γ-Aminobutyric Acid Receptor Agonists Product Portfolio
  132. 8.22.5 Sanofi Recent Developments
  133. 8.23 Shanghai Pharmaceuticals Holding
  134. 8.23.1 Shanghai Pharmaceuticals Holding Company Information
  135. 8.23.2 Shanghai Pharmaceuticals Holding Business Overview
  136. 8.23.3 Shanghai Pharmaceuticals Holding γ-Aminobutyric Acid Receptor Agonists Sales, Value and Gross Margin (2021-2026)
  137. 8.23.4 Shanghai Pharmaceuticals Holding γ-Aminobutyric Acid Receptor Agonists Product Portfolio
  138. 8.23.5 Shanghai Pharmaceuticals Holding Recent Developments
  139. 8.24 Sun Pharma
  140. 8.24.1 Sun Pharma Company Information
  141. 8.24.2 Sun Pharma Business Overview
  142. 8.24.3 Sun Pharma γ-Aminobutyric Acid Receptor Agonists Sales, Value and Gross Margin (2021-2026)
  143. 8.24.4 Sun Pharma γ-Aminobutyric Acid Receptor Agonists Product Portfolio
  144. 8.24.5 Sun Pharma Recent Developments
  145. 8.25 Teva
  146. 8.25.1 Teva Company Information
  147. 8.25.2 Teva Business Overview
  148. 8.25.3 Teva γ-Aminobutyric Acid Receptor Agonists Sales, Value and Gross Margin (2021-2026)
  149. 8.25.4 Teva γ-Aminobutyric Acid Receptor Agonists Product Portfolio
  150. 8.25.5 Teva Recent Developments
  151. 8.26 Takeda
  152. 8.26.1 Takeda Company Information
  153. 8.26.2 Takeda Business Overview
  154. 8.26.3 Takeda γ-Aminobutyric Acid Receptor Agonists Sales, Value and Gross Margin (2021-2026)
  155. 8.26.4 Takeda γ-Aminobutyric Acid Receptor Agonists Product Portfolio
  156. 8.26.5 Takeda Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 γ-Aminobutyric Acid Receptor Agonists Value Chain Analysis
  2. 9.1.1 γ-Aminobutyric Acid Receptor Agonists Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 γ-Aminobutyric Acid Receptor Agonists Sales Mode & Process
  6. 9.2 γ-Aminobutyric Acid Receptor Agonists Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 γ-Aminobutyric Acid Receptor Agonists Distributors
  9. 9.2.3 γ-Aminobutyric Acid Receptor Agonists Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst